Skip to main content
147 search results for:

Atezolizumab 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 28-07-2023 | Non-small-cell lung cancer | News | Article

    Atezolizumab may be beneficial for platinum-ineligible advanced NSCLC

    First-line treatment with atezolizumab significantly improves the overall survival of platinum-ineligible patients with locally advanced or metastatic non-small-cell lung cancer relative to chemotherapy.

  2. 11-09-2022 | ESMO 2022 | Conference coverage | Article

    IMmotion010 does not support adjuvant atezolizumab in intermediate-, high-risk RCC

    Adjuvant treatment with atezolizumab does not improve the outcomes of individuals with renal cell carcinoma at increased risk for recurrence after nephrectomy, indicate phase 3 trial results.

  3. 09-08-2022 | WCLC 2022 | Conference coverage | Article

    ​​​​​​​IMpower010 shows OS trend favoring adjuvant atezolizumab in certain NSCLC patients

    Adjuvant treatment with atezolizumab is associated with a trend toward improved overall survival relative to best supportive care in people with resected stage II–IIIA non-small-cell lung cancer positive for PD-L1, indicate IMpower010 results.

  4. 05-06-2022 | ASCO 2022 | Conference coverage | Article

    More support from COSMIC-021 for cabozantinib–atezolizumab potential in advanced UC

    The COSMIC-021 trial has shown promising efficacy and manageable toxicity of cabozantinib plus atezolizumab for both treatment-naïve and immune checkpoint inhibitor-treated advanced urothelial carcinoma.

  5. play
    03-06-2022 | ASCO 2022 | Conference coverage | Video

    COSMIC-021 cohorts continue to show encouraging cabozantinib–atezolizumab advanced UC activity

    Sumanta Pal outlines results from three cohorts of the COSMIC-021 trial pointing to the potential of combining cabozantinib with atezolizumab in treatment-naïve and pretreated advanced urothelial cancer. This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

  6. 04-06-2022 | ASCO 2022 | Conference coverage | Article

    COSMIC-021 points to cabozantinib–atezolizumab potential for ICI-treated metastatic NSCLC

    Cabozantinib in combination with atezolizumab has “encouraging” antitumor activity, while cabozantinib alone has “modest” activity, in people who have received prior immune checkpoint inhibitor treatment for advanced non-small-cell lung cancer, say trial investigators.

  7. 20-05-2022 | Non-small-cell lung cancer | News | Article

    First-line tiragolumab–atezolizumab promising for PD-L1-positive advanced NSCLC

    Previously untreated patients with PD-L1-positive advanced non-small-cell lung cancer could benefit from the combination of tiragolumab plus atezolizumab, indicate phase 2 trial data.

  8. 17-03-2022 | Triple-negative breast cancer | News | Article

    NeoTRIP: No pCR benefit from atezolizumab–chemotherapy in TNBC patients

    The addition of atezolizumab to neoadjuvant carboplatin and nab-paclitaxel does not significantly increase the rate of pathologic complete response among women undergoing surgery for treatment-naïve triple-negative breast cancer, research suggests.

  9. 14-02-2022 | Bladder cancer | News | Article

    Neoadjuvant atezolizumab–chemotherapy ‘worthy of investigation’ for MIBC

    Early trial findings indicate that adding atezolizumab to neoadjuvant gemcitabine plus cisplatin might improve the outcome of patients with muscle-invasive bladder cancer scheduled to undergo radical cystectomy.

  10. 20-10-2021 | FDA | News | Article
    approvalsWatch

    Adjuvant atezolizumab approved by FDA for NSCLC patients

    The announcement is based on the phase 3 IMpower010 trial , in which patients given adjuvant atezolizumab had significantly better disease-free survival than those who received best supportive care.

  11. 13-09-2021 | WCLC 2021 | Conference coverage | Article

    Atezolizumab plus chemotherapy feasible for NSCLC with brain metastases

    Treatment with carboplatin and pemetrexed plus atezolizumab shows promise for people with nonsquamous non-small-cell lung cancer and asymptomatic, untreated brain metastases, phase 2 study findings indicate.

  12. 30-09-2021 | ESMO 2021 | Conference coverage | Article

    Five-year IMvigor210 data confirm first-line atezolizumab mUC benefit

    Long-term follow-up of the phase 2 IMvigor210 trial points to the continued benefit of first-line treatment with atezolizumab monotherapy in cisplatin-ineligible patients with metastatic urothelial carcinoma. This independent news story was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

  13. 14-09-2021 | WCLC 2021 | Conference coverage | Article

    No new safety signals for neoadjuvant, maintenance atezolizumab in mesothelioma

    Neoadjuvant atezolizumab meets researcher-defined safety criteria for use in combination with cisplatin plus pemetrexed and then as postsurgical maintenance therapy for people with resectable malignant pleural mesothelioma.

  14. play
    15-06-2021 | ASCO 2021 | Conference coverage | Video

    IMpower010 supports adjuvant atezolizumab in early-stage NSCLC

    Heather Wakelee talks through the efficacy and safety data from the IMpower010 study of postoperative atezolizumab in individuals with early-stage non-small-cell lung cancer, touching on the cost aspect and outlining the key unanswered questions.

  15. 04-06-2021 | ASCO 2021 | Conference coverage | Article

    Adjuvant atezolizumab delays recurrence in early-stage NSCLC patients

    People with stage II–IIIA non-small-cell lung cancer derive a significant disease-free survival benefit from adjuvant treatment with atezolizumab versus best supportive care, according to phase 3 trial results.

  16. 28-06-2021 | Breast cancer | News | Article

    No pCR benefit of neoadjuvant atezolizumab addition in early breast cancer

    Adding atezolizumab to neoadjuvant dual-HER2 blockade plus chemotherapy does not boost pathologic complete response rates in people with high-risk, HER2-positive, early breast cancer, find the IMpassion050 investigators.

  17. 23-06-2021 | ASCO 2021 | Conference coverage | Article

    Rogaratinib plus atezolizumab shows ‘promising efficacy’ for selected cisplatin-ineligible advanced UC

    Phase 2 trial findings demonstrate potential for the first-line use of rogaratinib plus atezolizumab in cisplatin-ineligible patients with advanced urothelial carcinoma with FGFR1–3 mRNA overexpression or FGFR3 mutations. This independent news story was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

  18. 21-05-2021 | Urothelial cancer | News | Article
    News in brief

    Durable benefit with atezolizumab in some advanced urothelial cancer patients

    Updated results from the phase 3 IMvigor211 trial indicate that some patients with advanced urothelial cancer may derive a long-term benefit from atezolizumab after progression on platinum-based chemotherapy.

  19. 10-05-2021 | ESMO Breast 2021 | Conference coverage | Article

    GELATO: Atezolizumab–carboplatin promising for metastatic lobular breast cancer

    Early results from the GELATO trial point to the potential of atezolizumab plus carboplatin for the treatment of metastatic invasive lobular breast cancer.

  20. play
    11-02-2021 | ASCO GU 2021 | Conference coverage | Video

    Single-agent atezolizumab supported for some cisplatin-ineligible mUC patients

    Matthew Galsky shares exploratory data from the IMvigor130 trial suggesting the benefit of atezolizumab monotherapy in certain cisplatin-ineligible patients with advanced urothelial carcinoma. This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.